Cite
HARVARD Citation
Tsai, M. et al. (2023). Switching to coformulated bictegravir, emtricitabine, and tenofovir alafenamide maintained viral suppression in adults with historical virological failures and K65N/R mutation. International journal of infectious diseases. pp. 39-47. [Online].